Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07097311 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
A Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency, sponsored by Jerry Vockley, MD, PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT07097311 is a Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency that is actively recruiting participants, run by Jerry Vockley, MD, PhD. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07097311, a Phase 2 study of Medium-chain Acyl-CoA Dehydrogenase Deficiency, is actively recruiting participants, sponsored by Jerry Vockley, MD, PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of long chain fatty acid oxidation disorders (FAODs). Previous research suggests that triheptanoin may also be effective in the treatment MCADD. This study will investigate the safety and efficacy (how well it works) of triheptanoin patients with MCADD.
Conditions Studied
Interventions
- DRUG Triheptanoin
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07097311
The ClinicalTrials.gov registry entry for NCT07097311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jerry Vockley, MD, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medium-chain Acyl-CoA Dehydrogenase Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Triheptanoin is the first listed.
NCT07097311 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07097311 about?
NCT07097311 is a clinical study titled "Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)". This is a medical research study to test a medication in patients 4 years of age and older with a disease called medium-chain acyl-CoA dehydrogenase deficiency (MCADD). The medication is triheptanoin, which is currently FDA approved for the treatment of long chain fatty acid oxidation disorders (FAO...
What is the current status of trial NCT07097311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2026-07. Estimated completion is 2028-04.
What conditions does trial NCT07097311 study?
This clinical trial studies the following conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency.
What interventions are being tested in trial NCT07097311?
The interventions under investigation include: Triheptanoin (DRUG).
Who is sponsoring clinical trial NCT07097311?
This trial is sponsored by Jerry Vockley, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07097311 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medium-chain Acyl-CoA Dehydrogenase Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.